Meloxicam and selective COX-2 inhibition: the evidence for improved gastrointestinal tolerability


    loading  Checking for direct PDF access through Ovid

Abstract

IN BRIEFOf the currently available NSAIDs, meloxicam has the greatest selectivity for the cyclo-oxygenase-2 (COX-2) isoform of COX. COX-2 selectivity has been purported to confer improved gastrointestinal (GI) tolerability.Available data indicate that meloxicam generally has improved GI tolerability compared with piroxicam, diclofenac and naproxen. However, GI adverse events are still commonly reported in patients treated with meloxicam.The jury is still out on whether COX-2 selectivity will be the breakthrough required in the development of NSAIDs with improved GI tolerability.

    loading  Loading Related Articles